Am interested in knowing what the delay in the clinical trial here is all about? This would seem to be potentially an excellent product. Currently the only treatment option for locally invasive pancreatic cancer is gemcitabine-based chemotherapy which is toxic and usually ineffective. Patients develop progressive problems with biliary obstruction, duodenal obstruction, and/or pain, and localised brachytherapy would seem an ideal way of slowing that process significantly - very easy to apply via endoscopic ultrasound. There is also the potential for use in cystic neoplasms in the pancreas which tend to require lots of surveillance and occasionally surgery, so obliteration by brachytherapy could be very cost-effective. The only potential fish-hooks I could see is potential problems with radiation effects on surrounding structures e.g. portal vein, large arteries, duodenum/stomach, and possible competition from other radioisotopes such as I-125 which are available in some Asian countries. I wonder how strong the IP is here? They do need to get a move on.
OSL Price at posting:
9.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)